Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1980-12-16
|
| pubmed:abstractText |
In a prospective randomized study, the chemotherapeutic combination of high-dose methotrexate-citrovorum factor rescue plus cyclophosphamide (MECY) has been shown to be statistically significantly superior to the combination of 5-fluorouracil plus cyclophosphamide (FUCY) in the treatment of Stage III-IV ovarian adenocarcinoma. With MECY, an overall objective remission rate of 67% and a complete remission rate of 48% were achieved. All patients had undergone no treatment except for surgery. In addition to the chemotherapy, patients were randomly allocated to receive or not receive nonspecific immunotherapy with Corynebacterium parvum; this immunotherapy had no apparent effect on the chemotherapeutic response. The study demonstrates a high degree of activity for the MECY regimen, and a comparison between the results with MECY in this study and melphalan in an earlier prospective randomized study provides statistical evidence favoring MECY over single-agent melphalan in the treatment of this disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0008-543X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1333-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:6998553-Adenocarcinoma,
pubmed-meshheading:6998553-Adolescent,
pubmed-meshheading:6998553-Adult,
pubmed-meshheading:6998553-Aged,
pubmed-meshheading:6998553-Bacterial Vaccines,
pubmed-meshheading:6998553-Child,
pubmed-meshheading:6998553-Clinical Trials as Topic,
pubmed-meshheading:6998553-Cyclophosphamide,
pubmed-meshheading:6998553-Drug Administration Schedule,
pubmed-meshheading:6998553-Drug Therapy, Combination,
pubmed-meshheading:6998553-Female,
pubmed-meshheading:6998553-Humans,
pubmed-meshheading:6998553-Leucovorin,
pubmed-meshheading:6998553-Methotrexate,
pubmed-meshheading:6998553-Middle Aged,
pubmed-meshheading:6998553-Ovarian Neoplasms,
pubmed-meshheading:6998553-Propionibacterium acnes,
pubmed-meshheading:6998553-Prospective Studies
|
| pubmed:year |
1980
|
| pubmed:articleTitle |
High-dose methotrexate with "RESCUE" plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma. A randomized trial with observations on the influence of C parvum immunotherapy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|